- Home
- Products
- Customized ADCs
- CD40LG
- Anti-CD40LG (Dapirolizumab pegol)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC
Anti-CD40LG (Dapirolizumab pegol)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2449)
This ADC product is comprised of an anti-CD40LG Fab' fragment conjugated via a MC-Vc-PAB-DMEA-(PEG2) linker to duocarmycin SA. The duocarmycin SA is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, duocarmycin SA binds to DNA, causes DNA damage.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- CD40LG
- Alternative Names
- CD40LG; CD40 ligand; HIGM1, IMD3, TNFSF5, tumor necrosis factor (ligand) superfamily, member 5 (hyper IgM syndrome); CD40 antigen ligand; CD40L; CD154; gp39; hCD40L; hyper IgM syndrome; T B cell activating molecule; TNF related activation protein; TRAP; tumor necrosis factor (ligand) superfamily member 5; CD40-L; T-cell antigen Gp39; T-B cell-activating molecule; TNF-related activation protein; IGM; IMD3; HIGM1; T-BAM; TNFSF5;
- Target Entrez Gene ID
- 959
- Target UniProt ID
- P29965
- Overview
- The protein encoded by this gene is expressed on the surface of T cells. It regulates B cell function by engaging CD40 on the B cell surface. A defect in this gene results in an inability to undergo immunoglobulin class switch and is associated with hyper-IgM syndrome.
- Overview
- Humanized Anti-CD40LG IgG1-Fab’ fragment, Dapirolizumab pegol
- Generic name
- Dapirolizumab pegol
- Host animal
- Rat
- Name
- MC-Vc-PAB-DMEA-(PEG2)
- Description
- Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
- Name
- duocarmycin SA
- Description
- Duocarmycins SA belong to the minor-groove-binding DNA-alkylating agents (DNA MGBA). The natural duocarmycins are isolated from the culture broth of Streptmyces sp and a series of derivatives has also been synthesized.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-IL6R-SMCC-DM1 ADC (CAT#: ADC-W-1442)
- Anti-Fibrin II-beta chain (Biciromab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1997)
- Anti-MUC1 (Sontuzumab)-MC-MMAF ADC (CAT#: ADC-W-2488)
- Anti-CD74-VC-MMAE ADC-3 (CAT#: ADC-W-038)
- Anti-MSLN-Mc-VC-PABC-MMAE ADC-2 (CAT#: ADC-W-455)
- Anti-CCR5 (PRO 140)-SMCC-DM1 ADC (CAT#: ADC-W-764)
- Anti-AFP (Tacatuzumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-659)
- Anti-CMV (Sevirumab)-SMCC-DM1 ADC (CAT#: ADC-W-1976)
- Anti-FCER2 (Gomiliximab)-MC-MMAF ADC (CAT#: ADC-W-1144)
- Anti-IFNA1 (Faralimomab)-SPDB-DM4 ADC (CAT#: ADC-W-1221)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-2449. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-925 | Anti-CD40LG (Toralizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-916 | Anti-CD40LG (Ruplizumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-921 | Anti-CD40LG (Toralizumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-2444 | Anti-CD40LG (Dapirolizumab pegol)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-924 | Anti-CD40LG (Toralizumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2547 | Anti-CD44 (Bivatuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2603 | Anti-GPNMB (Glembatumumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2570 | Anti-MUC16 (Sofituzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2619 | Anti-MS4A1-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2564 | Anti-MSLN (Anetumab )-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2559 | Anti-CD79B (Polatuzumab )-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2588 | Anti-EGFR (Zalutumumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2615 | Anti-MS4A1 (Rituximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2597 | Anti-ERBB2 (Trastuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2547 | Anti-CD44 (Bivatuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
